Novo Nordisk Unveils Strategy For Dominating Diabetes Market In China
This article was originally published in PharmAsia News
Executive Summary
Novo Nordisk has carved out a dominant position in China's diabetic drug market despite launching only one oral hypoglycemic agent and insulin thanks to its 20-year presence in the country that allows the establishment of an extensive sales network. Its revenue is evenly split between key cities and periphery markets. The company's strategy is to actively conduct health education on diabetes in two areas, namely, mainstream patient education and physician training in communities. In addition, Novo Nordisk expects to make an official announcement this October about its plans to set up a plant in Tianjin that will supply products to China and more than 200 countries worldwide. (Click here for more - Chinese Language)